CAP Comments on CMS Antifraud Efforts, Urges Reevaluation of MolDX Program
The College of American Pathologists (CAP) submitted comments in response to a request for information on the Centers for Medicare & Medicaid...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3
TELCOR Acquires Sample Healthcare to Lead AI-Driven Transformation of Revenue Cycle Operations
Lincoln, NE — April 1, 2026 — TELCOR Inc, a leading provider of healthcare technology solutions for laboratories and healthcare facilities, today...
CMS Adopts Final Rule Phasing Out Fax and Mail for Health Care Claims Attachments
The Centers for Medicare & Medicaid Services (CMS) issued a final rule on national standards for electronic claims attachments and signatures,...